Life Technologies reported 0 in Interest Expense on Debt for its fiscal quarter ending in September of 2024.


Interest Expense On Debt Change Date
Ardelyx USD 6.58M 2.61M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Cipla 140.5M 300K Jun/2025
Clal Biotechnology 2.42M 640K Sep/2020
Compugen 1.28M 507K Sep/2024
CSL USD 240M 18M Dec/2024
Galapagos EUR 780K 49.34M Mar/2025
GlaxoSmithKline 184M 22M Jun/2025
Grifols EUR 197.61M 13.11M Sep/2024
Life Technologies 0 0 Sep/2024
Novartis USD 289M 19M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
United Therapeutics USD 7.3M 1.2M Jun/2025